🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchPemvidutide Phase 2 — NAFLD endpoints Page 4

Pemvidutide Phase 2 — NAFLD endpoints

MASHdoc_SA Sat, Jun 6, 2026 at 4:01 AM 20 replies 520 viewsPage 4 of 4
MarkLI_maint
Member
534
2,345
Jun 2024
Long Island, NY
Jun 7, 2026 at 9:16 AM#16
CarlaRPh_TPA said:
MASHdoc_SA said: ...regarding the trial evidence...

This is my experience too, for whatever a second data point is worth.

6 6RunnerRach, TrialNerd_Beth, HPLC_Greg and 3 others
Reply Quote Save Share Report
LondonLisa
Member
912
3,456
Mar 2024
London, UK
Jun 7, 2026 at 1:18 PM#17

One thing that is still open after pete_manc_UK’s answer:

Was that from a primary source or from a summary of one?

Last edited: Jun 7, 2026 at 3:18 PM
5 5Dr.MetabolicMD, RetaRick_CA, JenPlateau and 2 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Jun 7, 2026 at 5:20 PM#18
Dr.PulmRoch said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.

4 4BrianDallas92, labquiet_amy, emily_PDX and 1 other
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Jun 7, 2026 at 9:22 PM#19
Dr.PulmRoch said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

3 3stefan_berlin, Dr.EM_Chicago, pete_RVA
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 1:24 AM#20

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Report rather than reply if it drifts again.

31 6PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 28 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register